GT
BIO icon

Greenleaf Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Greenleaf Trust’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-629
Closed -$207K – 802
2024
Q4 		$207K Buy
629
+26
+4% +$8.82K ﹤0.01% 773
2024
Q3 		$202K Buy
+603
New +$192K ﹤0.01% 801
2024
Q2 		– Sell
-682
Closed -$236K – 799
2024
Q1 		$236K Sell
682
-13
-2% -$4.28K ﹤0.01% 692
2023
Q4 		$224K Buy
+695
New +$218K ﹤0.01% 688
2023
Q3 		– Sell
-551
Closed -$209K – 748
2023
Q2 		$209K Buy
551
+40
+8% +$16.3K ﹤0.01% 715
2023
Q1 		$245K Buy
+511
New +$239K ﹤0.01% 667
2022
Q3 		– Sell
-421
Closed -$208K – 716
2022
Q2 		$208K Sell
421
-23
-5% -$12K ﹤0.01% 666
2022
Q1 		$250K Sell
444
-18
-4% -$10.9K ﹤0.01% 651
2021
Q4 		$349K Buy
462
+33
+8% +$24.7K ﹤0.01% 549
2021
Q3 		$320K Buy
429
+18
+4% +$13.5K ﹤0.01% 552
2021
Q2 		$265K Buy
411
+5
+1% +$3.04K ﹤0.01% 619
2021
Q1 		$232K Buy
406
+20
+5% +$11.8K ﹤0.01% 642
2020
Q4 		$225K Buy
+386
New +$220K ﹤0.01% 565

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Greenleaf Trust's BIO Position: Q1 2025 in Review

Greenleaf Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 629 shares — an estimated $207K sold.

Greenleaf Trust first reported a position in BIO in Q4 2020 and held it in 13 quarters. The position peaked at $349K in Q4 2021. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Greenleaf Trust reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Greenleaf Trust sold 629 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $207K.
  • Greenleaf Trust first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 13 quarters.
  • Greenleaf Trust's Bio-Rad Laboratories Class A position peaked at $349K in Q4 2021.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Greenleaf Trust's 13F filing for Q1 2025, filed 30 Apr 2025.